Oculis (NASDAQ:OCS) Trading Down 1.1% - Should You Sell?

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was down 1.1% on Wednesday . The company traded as low as $18.37 and last traded at $18.43. Approximately 10,438 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 45,351 shares. The stock had previously closed at $18.64.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on OCS shares. Chardan Capital boosted their price target on Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a report on Friday, May 9th. HC Wainwright boosted their price target on Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, April 17th.

Oculis Stock Down 1.8%

The stock has a market capitalization of $788.50 million, a price-to-earnings ratio of -6.84 and a beta of 0.29. The company has a 50 day moving average of $18.95 and a 200 day moving average of $19.25.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The business had revenue of $0.32 million during the quarter, compared to analyst estimates of $0.22 million. Oculis had a negative net margin of 13,788.70% and a negative return on equity of 92.95%. On average, research analysts forecast that Oculis Holding AG will post -2.09 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bellevue Group AG purchased a new stake in shares of Oculis in the fourth quarter worth about $170,000. XTX Topco Ltd purchased a new stake in shares of Oculis in the fourth quarter worth about $225,000. Kestra Private Wealth Services LLC purchased a new stake in shares of Oculis in the first quarter worth about $234,000. Geode Capital Management LLC boosted its position in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after buying an additional 1,800 shares during the period. Finally, Citadel Advisors LLC purchased a new stake in shares of Oculis in the fourth quarter worth about $389,000. 22.30% of the stock is currently owned by institutional investors and hedge funds.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.